If the company wanted to maximise shareholder value, the only benefit in these FDA advances, and they are advances, is to leverage them into a US partnership deal.
The company can hang onto Europe and Australia.
But it MUST partner US and Asia.
It cannot manage those approval processes in those markets on its own. A partnership deal will see the share price rise, as it will give real credibility to the technology and remove the stigma around the current management's skills in regulatory approvals.
If the company wanted to maximise shareholder value, the only...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.001(12.5%) |
Mkt cap ! $30.58M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.9¢ | 0.8¢ | $114.3K | 13.41M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 9972750 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 22973299 | 19 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |